EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)
as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Elecsys AFP**
Art.-Nr./*Cat. No.*:	**07026706190**
Beschreibung/*Description*:	Immunologischer In-vitro-Test zur quantitativen Bestimmung von α1-Fetoprotein in Humanserum und -plasma. Dieser Test dient für folgende Anwendungszwecke: ▪ als Hilfsmittel bei der Diagnose des Leberzellkarzinoms (HCC). ▪ zur Unterstützung der Behandlung von Patienten mit nichtseminomatösen Keimzelltumoren. ▪ als eine Komponente zur Evaluierung des Risikos für Trisomie 21 (Down-Syndrom) in Kombination mit anderen Parametern. Zur Diagnose von Chromosomenaberrationen sind weitere Untersuchungen erforderlich. Der **E**lektro**C**hemi**L**umineszenz **I**mmuno**A**ssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen. *Immunoassay for the in vitro quantitative determination of α1-fetoprotein in human serum and plasma.* *This assay is intended for the use as:* ▪ *An aid in the diagnosis of hepatocellular carcinoma (HCC).* ▪ *An aid in the management of patients with non-seminomatous germ cell tumors.* ▪ *One component in combination with other parameters to evaluate the risk of trisomy 21 (Down syndrome). Further testing is required for diagnosis of chromosomal aberrations.* *The **e**lectro**c**hemi**l**uminescence **i**mmuno**a**ssay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Digitally signed by Lazari Cristina
Date: 2023.06.12 16:46:01 EEST
Reason: MoldSign Signature
Location: Moldova

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

Mannheim, 9 February 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)
as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Elecsys Anti-HBs II**
Art.-Nr./*Cat. No.*:	**08498610190**
Beschreibung/*Description*:	Immunologischer In-vitro-Test zur quantitativen Bestimmung von Humanantikörpern gegen das Hepatitis-B-Oberflächenantigen (HBsAg) in Humanserum und -plasma. Der **E**lektro**C**hemi**L**umineszenz-**I**mmuno**A**ssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen. *Immunoassay for the in vitro quantitative determination of human antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma.* *The **e**lectro**c**hemi**l**uminescence **i**mmuno**a**ssay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

Mannheim, 31 May 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
Ralf Zielenski
A45CC19E27A04F3...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:
Address:

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany

Single Registration Number: DE-MF-000006260

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	**Cat. No.**	**Basic UDI-DI**
Elecsys CA 19-9	11776193122	761333600730AH
Elecsys CA 19-9	11776193214	761333602081AD
Elecsys CA 19-9	07027028190	761333600799BM
CA 19-9 CalSet	11776215122	761333600732AM

Risk Class: ☐ *A* ☐ *B* ☒ *C* ☐ *D*

Conformity Route:

☐ *Self-Declaration of Conformity (Class A)*
☐ *Self-Declaration of Conformity after Notified Body involvement for sterile manufacturing conditions acc. Art. 48 (10) (Class A sterile)*
☒ *Technical Documentation Assessment Class B/C – Annex IX*
☐ *Technical Documentation Assessment Class D – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX*
☐ *Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX*

Certificates:

☒ *EU QM Certificate No.:* V12 010283 0639
☐ *EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):*

Other: ☐ *Common Specifications:*

Notified Body (NB) Name: *TÜV Süd Product Service GmbH*
NB Address: *Ridlerstraße 65*
80339 Munich
Germany
NB Ident. No.: *0123*

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 17 December 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
Ralf Zielenski
A7F0BA9FE91A46A...

Ralf Zielenski
Head Q&R Compliance, PRRC RDG
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer: *Address:*	Roche Diagnostics GmbH Sandhofer Strasse 116 68305 Mannheim Germany
Single Registration Number:	*TBD (application filed; confirmation pending)*
Authorized Representative: *Address:*	N/A
Single Registration Number:	N/A

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	**Cat. No.**	**Basic UDI-DI**
Elecsys CEA	04491777190	761333600279AN
Elecsys CEA	07027079190	761333600248AB
Elecsys CEA	11731629322	7613336001349T
CEA CalSet	11731645322	7613336001359V

Risk Class:	☐ *A* ☐ *B* ☒ *C* ☐ *D*
Conformity Route:	☐ *Self-Declaration of Conformity (Class A)* ☒ *Technical Documentation Assessment Class B/C – Annex IX* ☐ *Technical Documentation Assessment Class D – Annex IX* ☐ *Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX* ☐ *Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX* ☐ *Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX*
Certificates:	☒ *EU QM Certificate No.:* V12 010283 0639 ☐ *EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):*
Other:	☐ *Common Specifications:*
Notified Body (NB) Name: *NB Address:* *NB Ident. No.:*	*TÜV Süd Product Service GmbH* *Ridlerstraße 65* *80339 Munich* *Germany* *0123*

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 8 March 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:	Roche Diagnostics GmbH
Address:	Sandhofer Strasse 116 68305 Mannheim Germany
Single Registration Number:	*TBD (application filed; confirmation pending)*
Authorized Representative:	N/A
Address:	
Single Registration Number:	N/A

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	**Cat. No.**	**Basic UDI-DI**
Elecsys FT3 III	06437206190	761333600189AL
Elecsys FT3 III	07027362190	761333600255A8
FT3 III CalSet	06437222190	761333600190A5

Risk Class: ☐ *A* ☒ *B* ☐ *C* ☐ *D*

Conformity Route:
☐ *Self-Declaration of Conformity (Class A)*
☒ *Technical Documentation Assessment Class B/C – Annex IX*
☐ *Technical Documentation Assessment Class D – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX*
☐ *Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX*

Certificates:
☒ *EU QM Certificate No.:* V12 010283 0639
☐ *EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):*

Other: ☐ *Common Specifications:*

Notified Body (NB) Name:	*TÜV Süd Product Service GmbH*
NB Address:	*Ridlerstraße 65* *80339 Munich* *Germany*
NB Ident. No.:	*0123*

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 30 March 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EC Declaration of Conformity

as per Annex IV of the Regulation EU 2017/746 on in-vitro diagnostic medical devices

Manufacturer:	Roche Diagnostics GmbH
Address:	Sandhofer Strasse 116 68305 Mannheim Germany
Single Registration Number:	*TBD (application filed; confirmation pending)*
Authorized Representative:	N/A
Address:	
Single Registration Number:	N/A

Roche Diagnostics GmbH declares, under the sole responsibility, that the product/the product line

Product Name	**Cat. No.**	**Basic UDI-DI**
Elecsys FT4 III	07976836190	761333600494AU
Elecsys FT4 III	07976887190	761333600496AY
CalSet FT4 III	07976879190	761333600495AW

Risk Class: ☐ *A* ☒ *B* ☐ *C* ☐ *D*

Conformity Route:
☐ *Self-Declaration of Conformity (Class A)*
☒ *Technical Documentation Assessment Class B/C – Annex IX*
☐ *Technical Documentation Assessment Class D – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Self-Testing – Annex IX*
☐ *Technical Documentation Assessment Class B/C/D for Near-Patient Testing – Annex IX*
☐ *Technical Documentation Assessment Class C/D for Companion Diagnostics – Annex IX*

Certificates:
☒ *EU QM Certificate No.:* V12 010283 0639
☐ *EU Technical Documentation Assessment Certificate No. (Class D, Near-Patient Testing, Self-Testing and Companion Diagnostics):*

Other: ☐ *Common Specifications:*

Notified Body (NB) Name:	*TÜV Süd Product Service GmbH*
NB Address:	*Ridlerstraße 65* *80339 Munich* *Germany*
NB Ident. No.:	*0123*

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

to which this declaration relates fulfils the requirements of Regulation EU 2017/746 on in-vitro diagnostic medical devices.

Mannheim, 9 April 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Contact address:

Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)
as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Elecsys HBsAg II**
Art.-Nr./*Cat. No.*:	**08814848190**
Beschreibung/*Description*:	Immunologischer In-vitro-Test zur qualitativen Bestimmung von Hepatitis-B-Oberflächenantigen (HBsAg) in Humanserum und -plasma. Der **E**lektro**C**hemi**L**umineszenz **I**mmuno**A**ssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen. *Immunoassay for the in vitro qualitative determination of hepatitis B surface antigen (HBsAg) in human serum and plasma.* *The **e**lectro**c**hemi**l**uminescence **i**mmuno**a**ssay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 15 February 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890

EG-Konformitätserklärung/*EC Declaration of Conformity*

gemäß Anhang IV der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 mit TÜV SÜD Product Service GmbH (Ridlerstraße 65, 80339 München, Germany) als Notified Body (Nr. 0123)
as per Annex IV of Directive 98/79/EC of the European Parliaments and Council of 27 October 1998 via TÜV SÜD Product Service GmbH (Ridlerstrasse 65, 80339 Munich, Germany) as the Notified Body (No. 0123)

Hersteller/*Manufacturer*:	Roche Diagnostics GmbH
Adresse/*Address:*	Sandhofer Strasse 116 D-68305 Mannheim

Die Roche Diagnostics GmbH erklärt, dass das Produkt/die Produktfamilie
Roche Diagnostics GmbH declares that the product/the product line

Produktname/*Product name*:	**Elecsys Anti-HCV II**
Art.-Nr./*Cat. No.*:	**07026889190**
Beschreibung/*Description*:	Der Elecsys Anti-HCV II Test ist ein diagnostischer In-vitro-Test für den qualitativen Nachweis von Antikörpern gegen Hepatitis-C-Virus (HCV) in Humanserum und -plasma. Der **E**lektro**C**hemi**L**umineszenz **I**mmuno**A**ssay "ECLIA" ist zur Durchführung an **cobas e** Immunoassay-Systemen vorgesehen. *The Elecsys Anti-HCV II assay is an in vitro diagnostic test for the qualitative detection of antibodies to hepatitis C virus (HCV) in human serum and plasma.* *The **e**lectro**c**hemi**l**uminescence **i**mmuno**a**ssay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.*

auf das/die sich diese Erklärung bezieht, den Forderungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über In-vitro-Diagnostica (bzw. seine Umsetzung in nationales Recht der Mitgliedsstaaten in welchen das Produkt vermarktet werden soll) entspricht.
to which this declaration relates fulfils the requirements of Directive 98/79/EC of the European Parliament and Council of 27 October 1998 on in-vitro diagnostic medical devices (and its relevant transposition into the national laws of the Member States in which the device is intended to be placed on the market).

Mannheim, 10 February 2021

Roche Diagnostics GmbH

ppa./*on behalf of the company*

DocuSigned by:
0AFDA3CC08B94C8...

Ralf Zielenski
Head of Quality
Centralised and Point of Care Solutions

ppa./*on behalf of the company*

DocuSigned by:
Stefan Scheib
FC5EDEC1054B44C...

Dr. Stefan Scheib
Director Global Regulatory Affairs
Centralised and Point of Care Solutions

Kontaktadresse/*Contact address*: Roche Diagnostics GmbH
Abt./*Dept.* Global Regulatory Affairs
Sandhofer Strasse 116
D-68305 Mannheim

Roche Diagnostics GmbH; Sandhofer Strasse 116; D-68305 Mannheim; Telefon +49-621-759-0; Telefax +49-621-759-2890